Park Sang Hyoung, Kim Shin, Ko Ok Bae, Koo Ja Eun, Lee Danbi, Jeong Yong Pil, Huh Jooryung, Kim Sung-Bae, Kim Sang We, Lee Jae-Lyun, Suh Cheolwon
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Korean J Intern Med. 2006 Sep;21(3):159-64. doi: 10.3904/kjim.2006.21.3.159.
The ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to determine whether ESHAP therapy would be effective and well-tolerated in Korean patients.
Twenty two patients with refractory or relapsed NHLs (all aggressive types) were enrolled in this study. We retrospectively evaluated the treatment response, the survival rate and the time to progression.
Six patients (27.3%) attained complete remission and eight patients (36.4%) attained partial remission. The overall response rate was 63.6%. The median survival duration was 15.5 months (95% confidence interval; 10.7 to 20.3 months), and the median duration of the time to progression was 8.3 months (95% confidence interval; 0.3 to 16.3 months). Myelosuppression was the major toxicity, but severe neutropenia or thrombocytopenia was rare, and renal toxicity was also infrequent.
ESHAP regimen is effective in Korean patients suffering with relapsed or refractory NHLs, but a more effective salvage modality is needed because of the short duration of remission and the insignificant impact on long-term survival.
ESHAP化疗方案，即依托泊苷、甲泼尼龙、大剂量阿糖胞苷和顺铂联合使用，在先前的治疗试验中已显示对复发性或难治性非霍奇金淋巴瘤（NHL）有效。我们试图确定ESHAP疗法在韩国患者中是否有效且耐受性良好。
22例难治性或复发性NHL患者（均为侵袭性类型）纳入本研究。我们回顾性评估了治疗反应、生存率和疾病进展时间。
6例患者（27.3%）达到完全缓解，8例患者（36.4%）达到部分缓解。总缓解率为63.6%。中位生存时间为15.5个月（95%置信区间：10.7至20.3个月），疾病进展时间的中位持续时间为8.3个月（95%置信区间：0.3至16.3个月）。骨髓抑制是主要毒性，但严重中性粒细胞减少或血小板减少很少见，肾毒性也不常见。
ESHAP方案对韩国复发性或难治性NHL患者有效，但由于缓解期短且对长期生存影响不显著，需要更有效的挽救治疗方式。
